Roche Holding AG
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
- Introduction
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.
Non-Interventional Study of Xeloda (Capecitabine) in Patients With Gastric Cancer
- Conditions
- Gastric Cancer
- First Posted Date
- 2014-10-24
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 223
- Registration Number
- NCT02274376
A German Study Evaluating the Efficacy and the Benefit of Integrated Personalized Diabetes Management (PDM) for Type 2 Diabetes Patients.
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Device: Accu-Chek Smart Pix readout DeviceDevice: Accu-Chek Smart Pix Software
- First Posted Date
- 2014-10-20
- Last Posted Date
- 2017-11-24
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 414
- Registration Number
- NCT02268929
Observational Study of Pertuzumab Safety in Participants With Breast Cancer
- First Posted Date
- 2014-10-16
- Last Posted Date
- 2021-05-03
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 1130
- Registration Number
- NCT02266173
- Locations
- 🇰🇷
Inje university Haeundae Paik Hospital, Busan, Korea, Republic of
🇰🇷Pusan National University Hospital, Busan, Korea, Republic of
🇰🇷Kyungpook National University Chilgok Hospital, Daegu, Korea, Republic of
A Study of Pegylated Interferon Alfa-2A in Combination With Lamivudine or Entecavir Compared With Untreated Control Group in Children With Hepatitis B Envelope Antigen (HBeAg)-Positive Chronic Hepatitis B (CHB) in the Immune-Tolerant Phase
- Conditions
- Pediatric Immuno-Tolerant Chronic Hepatitis B
- Interventions
- First Posted Date
- 2014-10-13
- Last Posted Date
- 2020-08-24
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 62
- Registration Number
- NCT02263079
- Locations
- 🇧🇪
Cliniques Universitaires St-Luc, Bruxelles, Belgium
🇮🇹Azienda Ospedaliero-Universitaria Policlinico S. Orsola Malpighi; U.O. Malattie Infettive, Bologna, Emilia-Romagna, Italy
🇩🇪Universitätsklinikum Essen; Klinik für Kinder- und Jugendmedizin Pädiatrie II, Essen, Germany
An Observational, Prospective, Safety Study of Mircera (Monopegylated Epoetin Beta) in Clinical Practice
- First Posted Date
- 2014-10-13
- Last Posted Date
- 2016-09-07
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 748
- Registration Number
- NCT02263833
A Study of Polatuzumab Vedotin (DCDS4501A) in Combination With Rituximab or Obinutuzumab Plus Bendamustine in Participants With Relapsed or Refractory Follicular or Diffuse Large B-Cell Lymphoma
- Conditions
- Lymphoma
- Interventions
- Drug: Polatuzumab vedotin (Liquid)Drug: Polatuzumab vedotin (Lyophilized)
- First Posted Date
- 2014-10-06
- Last Posted Date
- 2022-11-14
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 331
- Registration Number
- NCT02257567
- Locations
- 🇳🇱
UMC St. Radboud; Hematology, Nijmegen, Netherlands
🇺🇸University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸Swedish Cancer Inst., Seattle, Washington, United States
A Study of RO5186582 Treatment on Cytochrome P450 (CYP) 3A4 Activity in Healthy Participants
- Conditions
- Healthy Volunteer
- Interventions
- First Posted Date
- 2014-10-02
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 12
- Registration Number
- NCT02254759
Study of Tocilizumab (RoActemre) Administered Subcutaneously in Participants With Rheumatoid Arthritis in Everyday Clinical Practice
- Conditions
- Rheumatoid Arthritis
- First Posted Date
- 2014-09-29
- Last Posted Date
- 2020-09-22
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 1454
- Registration Number
- NCT02251860
- Locations
- 🇩🇪
CIRI - Centrum für Innovative Diagnostik und Therapie Rheumatologie/ Immunologie (GmbH), Frankfurt, Germany
A Study Investigating the Efficacy and Safety of Lampalizumab Intravitreal Injections in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration
- First Posted Date
- 2014-09-25
- Last Posted Date
- 2019-06-26
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 906
- Registration Number
- NCT02247479
- Locations
- 🇺🇸
Texas Retina Associates, Arlington, Texas, United States
🇺🇸Orange County Retina Med Group, Santa Ana, California, United States
🇺🇸Maine Eye Center, Portland, Maine, United States
A Study Investigating the Safety and Efficacy of Lampalizumab Intravitreal Injections in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration
- First Posted Date
- 2014-09-25
- Last Posted Date
- 2019-10-15
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 975
- Registration Number
- NCT02247531
- Locations
- 🇺🇸
Southern Vitreoretinal Assoc, Tallahassee, Florida, United States
🇺🇸Retina Health Center, Fort Myers, Florida, United States
🇺🇸Retina Consultants of Orange County, Fullerton, California, United States